Key result
Cardiac disorders occurred in 26% of patients receiving CAR-T cell therapy, with severe grade 3-5 disorders occurring in 10% of patients and strongly associating with severe cytokine release syndrome.
Why the study?
Data characterizing cardiac disorders in patients receiving CAR-T cell therapy for hematological malignancies are limited.
Population
126 patients with hematologic malignancies receiving CAR-T cell therapy
Design
Single-centre retrospective study
Authors
Loading...
May warrant cardiac monitoring during CAR-T therapy; leaves open confirmation of incidence and preventive impact in prospective studies.
Cohort (n=126)
No
Cardiac disorders are common but mostly mild following CAR-T cell therapy, and severe cases are strongly associated with higher grade cytokine release syndrome.
Qi et al. (2021) conducted a cohort in Relapsed/refractory hematologic malignancies (n=126). CAR-T cell therapy was evaluated on Occurrence of cardiac disorders (CTCAE defined). Cardiac disorders occurred in 26% of patients receiving CAR-T cell therapy, with severe grade 3-5 disorders occurring in 10% of patients and strongly associating with severe cytokine release syndrome.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: